Skip to main content
SpringerLink
Log in

The Role of Antioxidant Drugs in Oxidative Injury of Cardiovascular Tissue

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  1. Kramer JH, Phillips TM, Weglicki WB. Magnesiumdefi ciency enhanced post-ischemic myocardial injury is reduced by substance P receptor blockade. J Mol Cell Cardiol 1997;29:97–110.

    Google Scholar 

  2. Kramer JH, Mišík V, Weglicki WB. Magnesium-deficiency potentiates free radical production associated with post-ischemic injury to rat hearts: Vitamin E affords protection. Free Rad Biol Med 1994;16:713–723.

    Google Scholar 

  3. Kramer JH, Mišík V, Weglicki WB. Lipid peroxidation-derived free radical production and post-ischemic myocardial reperfusion injury. Ann N Y Acad Sci 1994;723:180–196.

    Google Scholar 

  4. Mergner GW, Weglicki WB, Kramer JH. Post-ischemic free radical production in the venous blood of the regionally-ischemic swine heart: Effect of deferoxamine. Circulation 1991;84(5):2079–2090.

    Google Scholar 

  5. Arroyo CM, Kramer JH, Leiboff RH, Mergner GW, Dickens BF, Weglicki WB. Spin trapping of oxygen and carbon-centered free radicals in ischemic canine myocardium. Free Rad Biol Med 1987;3:313–316.

    Google Scholar 

  6. Kramer JH, Arroyo CM, Dickens BF, Weglicki WB. Spintrapping evidence that graded myocardial ischemia alters post-ischemic superoxide production. Free Rad Biol Med 1987;3:153–159.

    Google Scholar 

  7. Tortolani AJ, Powell SR, Misik V, Weglicki WB, Pogo GJ, Kramer JH. Detection of free radicals in coronary sinus blood from patients undergoing elective cardioplegia. Free Rad Biol Med 1993;14:421–426.

    Google Scholar 

  8. Mak IT, Weglicki WB. Protective effect of b-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circ Res 1988;63:262–266.

    Google Scholar 

  9. Mak IT, Arroyo CM, Weglicki WB. Inhibition of sarcolemmal carbon-centered free radical formation by propranolol. Circ Res 1989;65:1151–11 56.

    Google Scholar 

  10. Weglicki WB, Mak IT, Simic M. Mechanisms of cardiovascular drugs as antioxidants. JMCC 1990;22:1199–1208.

    Google Scholar 

  11. Mak IT, Weglicki WB. Comparative antioxidant activities of propranolol, nifedipine, verapamil and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 1990;66:1449–1452.

    Google Scholar 

  12. Mak IT, Kramer JH, Freedman T, Tze S, Weglicki WB. Oxygen radical mediated injury of myocytes—Prevention by propranolol. JMCC 1990;22:687–695.

    Google Scholar 

  13. Mak IT, Kramer JH, Weglicki WB. Antioxidant properties of active and inactive isomers of nicardipine in cardiac membranes, endothelial cells and perfused rat hearts. Coronary Artery Disease 1992;3:1095–1103.

    Google Scholar 

  14. Kramer JH, Mak IT, Freedman A, Weglicki WB. Propranolol reduces anoxia/reoxygenation mediated injury of adult myocytes through an antiradical mechanism. JMCC 1991;23:1231–1244.

    Google Scholar 

  15. Freedman AM, Atrakchi AH, Cassidy MM, Weglicki WB. Magnesium deficiency-induced cardiomyopathy: Protection by vitamin E. Biochem Biophys Res Commun 1990;170:1102–1106.

    Google Scholar 

  16. Atrakchi AH, Bloom S, Dickens BF, Mak IT, Weglicki WB. Hypomagnesemia and isoproterenol cardiomyopathies: Protection by probucol. J Cardiovasc Pathol 1992;1:155–160.

    Google Scholar 

  17. Weglicki WB, Stafford RE, Cassidy MM, Phillips TM. Modulation of cytokines and cardiomyopathic lesions in a magnesium-deficient rodent model: effects of vitamin E and chloroquine. Am J Physiol 1993;264:C723–C726.

    Google Scholar 

  18. Weglicki WB, Freedman AM, Bloom S, Atrakchi AH, Cassidy MM, Dickens BF, Mak IT. Antioxidants and the cardiomyopathy of Mg-deficiency. Am J Cardiovasc Pathol 1992;4:210–215.

    Google Scholar 

  19. Mak IT, Weglicki WB. Membrane antiperoxidative activities of D-propranolol, L-propranolol and dimethyl-quaternary propranolol. Pharmacol Res 1990;25:25–30.

    Google Scholar 

  20. Mak IT, Weglicki WB. Beta-blockers with antioxidant properties: From propranolol to carvedilol. In: Free Radicals, Lipoprotein Oxidation and Atherosclerosis, Bellom G, Finardi, Maggie E, Rice-Evans C, eds. London: Richelieu Press, 1995;457–472.

    Google Scholar 

  21. Freedman A, Kramer JH, Mak IT, Cassidy MM, Weglicki WB. Propranolol preserves ultrastructure in adult cardiocytes exposed to anoxia/reoxygenation: A morphometric analysis. Free Rad Biol Med 1991;11:197–206.

    Google Scholar 

  22. Janero DR, Lopez R, Pittman J, Burghardt B. Propranolol as xanthine oxidase inhibitor: Implications for antioxidant activity. Life Sci 1989;44:1579–1585.

    Google Scholar 

  23. Aruoma OI, Smith C, Cecchini R, Evans PJ, Halliwell B. Free radical scavenging and inhibition of lipid peroxidation by beta-blockers and by agents that interfere with calcium metabolism. Biochem Pharmacol 1991;42:735–743.

    Google Scholar 

  24. Sugawara H, Tobise K, Onodera S. Absence of antioxidant effects of nifedipine and diltiazem on myocardial membrane lipid peroxidation in contrast with those of nisoldipine and propranolol. Biochem Pharmacol 1994;47:887–892.

    Google Scholar 

  25. Weksler BB, Gillick M, Pink J. Effect of propranolol on platelet function. Blood 1977;49:185–196.

    Google Scholar 

  26. Pruett JK, Walle T, Walle U. Propranolol effects of membrane repolarization time in isolated canine Purkinje fibers: Threshold tissue content and the in_uence of exposure time. J Pharmacol Exp Ther 1980;215:539–543.

    Google Scholar 

  27. Khaper N, Rigatto C, Seneviratne C, Li T, Singal PK. Chronic treatment with propranolol induces antioxidant changes and protects against ischemia-reperfusion injury. J Mol Cell Cardiol 1997;29:3335–3344.

    Google Scholar 

  28. Yue TL, McKenna PJ, Ruffolo RR Jr, Feurerstein GZ. Carvedilol, a new b-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol 1992;214:277–280.

    Google Scholar 

  29. Mak I T, Kramer J H, Weglicki W B. Potentiation of free radical-induced lipid peroxidative injury to sarcolemmal membranes by lipid amphiphiles. J Biol Chem 261(3): 1153–1157, 1986.

    Google Scholar 

  30. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res 1992;70:1099–1103.

    Google Scholar 

  31. Mak IT, Weglicki WB. Antioxidant properties of calcium channel blocking drugs. Methods Enzymol 1994;234: 620–630.

    Google Scholar 

  32. Kramer JH, Weglicki WB. A hydroxylated analog of the b-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Free Rad Biol Med 1996;21:813–825.

    Google Scholar 

  33. Bril A, Slivjak MJ, Dimartino MJ, Feurerstein GZ, Linee P, Poyser RH, Ruffolo RR Jr, Smith EF III. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: Comparison with propranolol. Cardiovasc Res 1992;26: 518–525.

    Google Scholar 

  34. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–1355.

    Google Scholar 

  35. Mak IT, Freedman A, Dickens BF, Weglicki WB. Protective effects of of SH-ACE inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990;40:2169–2174.

    Google Scholar 

  36. Bagchi D, Prasad R, Das DK. Direct scavenging of free radicals by captopril, an ACE inhibitor. Biochem Biophys Res Comm 1989;158:52–57.

    Google Scholar 

  37. Aruoma OI, Akanmu D, Cecchini R, Halliwell B. Evaluation of the ability of the ACE inhibitor captopril to scavenge reactive oxygen species. Chem Biol Interact 1991;77: 303–314.

    Google Scholar 

  38. Kettle AJ, Winterbourn CC. Superoxide enhances hypochlorous acid production by stimulated human neutrophils. Biochim Biophys Acta 1990;1052:379–385.

    Google Scholar 

  39. Westlin W, Mullane K. Does captopril attenuate reperfusioninduced myocardial dysfunction by scavenging free radicals? Circulation 1988;77:130–139.

    Google Scholar 

  40. Anderson B, Khaper N, Dhalla AK, Singal PK. Anti-free radical mechanisms in captopril protection against reperfusion injury in isolated rat hearts. Can J Cardiol 1996;12: 1099–1104.

    Google Scholar 

  41. Steinberg D, Parthasarathy S, Carew T, Khoo J, Witztum J. Beyond Cholesterol, modification of low density lipoprotein that increases its atherogenicity. N Engl J Med 1989;329: 915–918.

    Google Scholar 

  42. Steinberg D. Studies on the mechanism of probucol. Am J Cardiol 1986;57:16H–21H.

    Google Scholar 

  43. Mak IT, Murphy A, Hopper A, Witiak D, Ziemniak J, Weglicki WB. Potent inhibitory activities of hydrophobic aci-reductones against membrane and human LDL oxidation. Biochem Pharmcol 1998;55:1921–1926.

    Google Scholar 

  44. Kaul N, Siveski-Iliskovic N, Hill M, Khaper N, Seneviratne C, Singal PK. Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. Mol Cell Biochem 1996;160-161:283–288.

    Google Scholar 

  45. Kaul N, Siveski-Iliskovic N, Thomas TP, Hill M, Khaper N, Singal PK. Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition 1995;11:551–554.

    Google Scholar 

  46. Singal PK, Siveski-Iliskovic N, Hill M, Thomas TP, Li T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 1995;27: 1055–1063.

    Google Scholar 

  47. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects againts adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995;91:10–15.

    Google Scholar 

  48. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994;89:2829–2835.

    Google Scholar 

  49. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900–905.

    Google Scholar 

  50. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, De Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl Med 1997;337:365–372.

    Google Scholar 

  51. Freedman AM, Cassidy MM, Weglicki WB. Captopril protects against myocardial injury by magnesium deficiency. Hypertension 1991;18:142–147.

    Google Scholar 

  52. Freedman AM, Cassidy MM, Weglicki WB. Propranolol reduces cardiomyopathic injury induced by magnesium deficiency. Magnes Trace Elem 1992;10:348–354.

    Google Scholar 

  53. Singal PK, Kapur N, Dhillon KS, Beamish RE, Dhalla NS. Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol 1982;60: 1390–1397.

    Google Scholar 

  54. Singal PK, Beamish RE, Dhalla NS. Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv Exp Med Biol 1983;161:391–401.

    Google Scholar 

  55. Kirshenbaum LA, Gupta M, Thomas TP, Singal PK. Antioxidant protection against adrenaline-induced arrhythmias in rats with chronic heart hypertrophy. Can J Cardiol 1990;6:71–74.

    Google Scholar 

  56. Weglicki WB, Phillips TM. Pathobiology of magnesium deficiency: A cytokine/neurogenic in_ammation hypothesis. Am J Physiol 1992;263:R734–R737.

    Google Scholar 

  57. Mak IT, Dickens BF, Komarov AM, Phillips TM, Weglicki WB. Activation of the neutrophil and loss of plasma glutathione during Mg-deficiency—Modulation effect by NOS inhibition. Mol Cell Biochem 1997;176:35–39.

    Google Scholar 

  58. Itokawa Y. Tissue minerals of Mg-deficient rats with thiamine deficiency and excess. Magnesium 1987;6:48–54.

    Google Scholar 

  59. Weglicki WB, Phillips TM, Cassidy MM, Mak IT, Dickens BF, Stafford RE, Kramer JH. Pro-oxidant stress in Mgdeficiency: Role of neuropeptides and cytokines. In: The Oxygen Paradox, Davies KJA, Ursini F, eds. Padova, Italy: Cleop University Press, 1995;773–782.

    Google Scholar 

  60. Mak IT, Stafford RE, Weglicki WB. Loss of red cell glutathione during Mg deficiency: Prevention by vitamin E, D-propranolol, and chloroquine. Am J Physiol 1994;267:C1366–C1370

    Google Scholar 

  61. Stafford RE, Mak IT, Kramer JH, Weglicki WB. Protein oxidation in magnesium-deficient rat brains and kidneys. Biochem Biophys Res Commun 1993;28:569–600.

    Google Scholar 

  62. Weglicki WB, Mak IT, Phillips TM. Blockade of cardiac inflammlation in Mg-deficiency by substance P receptor inhibition. Circ Res 1994;24:1009–1013.

    Google Scholar 

  63. Weglicki WB, Mak IT, Stafford RE, Dickens BF, Cassidy MM, Phillips TM. Neurogenic peptides and the cardiomyopathy of Mg-deficiency: Effects of substance P-receptor inhibition. Mol Cell Biochem 1994;130:103–109.

    Google Scholar 

  64. Weglicki WB, Dickens BF, Mak IT, Kramer JH, Stafford RE, Cassidy MM, Phillips TM. Role of tissue and circulating substance P in cardiovascular injury associated with Mgdefi ciency. In: Dhalla NS, Singal PK, Takeda N, Beamish RE, eds. Pathophysiology of Heart Failure. Boston: Kluwer Academic Publishers, 1995;9–19.

    Google Scholar 

  65. Weglicki WB, Mak IT, Kramer JH, Dickens BF, Cassidy MM, Stafford RE, Phillips TM. Role of free radicals and substance P in magnesium deficiency. Cardiovasc Res 1996;31:677–682.

    Google Scholar 

  66. Weglicki WB, Mak IT. Commentary on magnesum deficiency, substance P receptor up-regulation and NO overproduction. Mag Res 1997;9:331–332.

    Google Scholar 

  67. Manty PW. Substance P and the inflammatory and immune response. Ann NY Acad Sci 1991;632:263–271.

    Google Scholar 

  68. Weglicki WB, Dickens BF, Wagner TL, Chmielinska JJ, Phillips TM. Immunoregulation by neuropeptides in Mgdefi ciency: Ex vivo effect of enhanced substance P production on circulating T lymphocytes from Mg-deficient mice. Mag Res 1996;9:3–11.

    Google Scholar 

  69. Jurjus AR, Walsh R, Weglicki WB, Correa-de-Araujo R. Increase in the expression of substance P receptors in the atria of magnesium-deficient rats. Cardiovasc Pathobiol 1998;2:199–206

    Google Scholar 

  70. Mak IT, Dickens BF, Weglicki WB.Substance P receptor blockade prevents neutrophil activation induced by Mgdefi ciency. Free Rad Biol Med 1998;25(Abstract):S45.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physiology and Experimental Medicine, The George Washington University Medical Center, Washington, DC

    W.B. Weglicki, J.H. Kramer & I.T. Mak

Authors
  1. W.B. Weglicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J.H. Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I.T. Mak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weglicki, W., Kramer, J. & Mak, I. The Role of Antioxidant Drugs in Oxidative Injury of Cardiovascular Tissue. Heart Fail Rev 4, 183–192 (1999). https://doi.org/10.1023/A:1009832726736

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009832726736

Keywords

Search

Navigation